Clinical Immunotherapeutics

, Volume 1, Issue 2, pp 135–147 | Cite as

Immunological Therapy of Breast Cancer

Current Status and Future Potential
  • Joseph A. Sparano
  • Kevin O’Boyle
Review Article Disease Treatment Review

Summary

Clinical trials of immunotherapy in patients with breast cancer have been limited. Although immune function does not appear to be depressed in patients with operable breast cancer, immune function may play a role in preventing tumour recurrence in such patients. For example, 2 features associated with an adverse prognosis include peripheral blood lymphocytopenia and lack of reactivity against autologous tumour in skin windows.

A number of agents that specifically or nonspecifically augment immunity have been studied. These include levamisole, the interferons, interleukin-2, cyclosporin, tumour vaccines, monoclonal antibodies and immunotoxins. Most of these trials have involved treatment of patients with advanced disease, and little antineoplastic activity has been demonstrated in this setting. Randomised trials have found no proven benefit for treatment with interferon-α or levamisole in addition to standard chemotherapy in patients with breast cancer, although these agents may not have been used optimally in these studies.

Improved understanding of the biology of breast cancer is likely to result in more rationally designed biological therapies employing entirely new treatment strategies, or using currently available drugs more effectively. Furthermore, levamisole combined with fluorouracil in patients with Duke’s C colon cancer can result in an improved outcome when compared with fluorouracil alone. This suggests that carcinomas of glandular origin may be immunologically responsive, and that it may be possible to produce clinical benefit with immunological therapies even if the precise basis for the benefit has not been defined.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Smith MA, Parkinson DR, Cheson BD, et al. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839–64PubMedGoogle Scholar
  2. 2.
    Liotta LA, Stetler-Stevenson WG. Principles of molecular cell biology of cancer: cancer metastasis. In: DeVita VT, et al., editors. Cancer: principles and practice of oncology. Philadelphia: JP Lippincott, 1993: 134Google Scholar
  3. 3.
    Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931–4PubMedGoogle Scholar
  4. 4.
    Lippman ME. The developments of biological therapies for breast cancer. Science 1993: 259: 631–2PubMedCrossRefGoogle Scholar
  5. 5.
    Krensky AM, Weiss A, Crabtree G, et al. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990; 322: 510–7PubMedCrossRefGoogle Scholar
  6. 6.
    Remick SC. Metastatic breast cancer in a young patient seropositive for human immunodeficiency virus. J Natl Cancer Inst 1991; 83: 447–8PubMedCrossRefGoogle Scholar
  7. 7.
    Yasumura T, Ohnori Y, Aikawa I, et al. Breast cancer arising de novo in recipients of kidney allograft. Jpn J Surg 1989; 99: 370–5CrossRefGoogle Scholar
  8. 8.
    Penn I. Cancer complicating organ transplantation. N Engl J Med 1990; 323; 1767PubMedCrossRefGoogle Scholar
  9. 9.
    Pattison CW, Woods KL, Morrison JM. Lymphocytopenia as an independent predictor of early recurrence in breast cancer. Br J Cancer 1987; 56: 75–6CrossRefGoogle Scholar
  10. 10.
    Kurtz JM, Jacquemier J, Amalric R, et al. Why are local recurrences after breast conserving therapy more frequent in younger patients? J Clin Oncol 1990; 8: 591–8PubMedGoogle Scholar
  11. 11.
    Bonilla F, Alvarez-Mon M, Merino, et al. Interleukin-2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients. Cancer 1988; 61: 629–34PubMedCrossRefGoogle Scholar
  12. 12.
    Espevik T, Waage A, Faxvaag LA, et al. Regulation of interleukin-2 and interleukin-6 production from T-cells: involvement of interleukin-1 and transforming growth factor-beta. Cell Immunol 1990; 126: 47–56PubMedCrossRefGoogle Scholar
  13. 13.
    Levy S, Herberman R, Lippman M, et al. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol 1987; 5: 348–53PubMedGoogle Scholar
  14. 14.
    Zielinski C, Tichatschek E, Muller C, et al. Association of increased lytic effector cell function with high estrogen receptor levels in tumor-bearing patients with breast cancer. Cancer 1989; 63: 1985–9PubMedCrossRefGoogle Scholar
  15. 15.
    Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76; 2421–38PubMedGoogle Scholar
  16. 16.
    Black MM, Zachrau RE, Hankey BF, et al. Skin window reactivity to autologous breast cancer. Cancer 1988; 62: 72–83PubMedCrossRefGoogle Scholar
  17. 17.
    Lacour J, Lacour F, Ducot B, et al. Polyadenylic-polyuridylic acid as adjuvant in the treatment of operable breast cancer: recent results. Eur J Surg Oncol 1988; 14: 311–6PubMedGoogle Scholar
  18. 18.
    Stevenson HC, Green I, Hamilton JM, et al. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 1991; 11: 2052–66Google Scholar
  19. 19.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339; 1–15, 71-85Google Scholar
  20. 20.
    Aisner J, Weinberg V, Perloff M, et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF Each + MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol 1987; 5: 1523–33PubMedGoogle Scholar
  21. 21.
    Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8PubMedCrossRefGoogle Scholar
  22. 22.
    Buroker TR, Moertel CG, Fleming TR, et al. A controlled evaluation of recent approaches to biochemical modulation or enhancement of fluorouracil therapy in colorectal carcinoma. J Clin Oncol 1985; 3: 1624–31PubMedGoogle Scholar
  23. 23.
    Goldstein D, Laszlo J. Interferon therapy: from imaginon to interferon. Cancer Res 1986; 46: 4315–29PubMedGoogle Scholar
  24. 24.
    van den Berg HW, Leahey EJ, Lynch M, et al. Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitises them to the anti-proliferative effects of tamoxifen. Br J Cancer 1987; 55: 255–7PubMedCrossRefGoogle Scholar
  25. 25.
    Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 3673–86Google Scholar
  26. 26.
    Ezekowitz RAB, Mullikien JB, Folkman J. Interferon alfa 2a for life-threatening hemangiomas of infancy. N Engl J Med 1992: 326: 1456–63PubMedCrossRefGoogle Scholar
  27. 27.
    White CW, Sondheimer HM, Crouch EC, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197–200PubMedCrossRefGoogle Scholar
  28. 28.
    Scala S, Murphy LD, Torrtora G, et al. Effects of differentiating agents on P-glycoprotein expression in a multidrug resistant breast cancer cell line [abstract]. Proc Am Assoc Cancer Res 1991; 32: 2240Google Scholar
  29. 29.
    Scala S, Pacelli R, Vincenzo R, et al. Reversal of adriamycin resistance by recombinant α-interferon in multidrug resistant human colon carcinoma LoVo-doxorubicin cells. Cancer Res 1991; 51: 4898–902PubMedGoogle Scholar
  30. 30.
    Verrelle P, Meissonier F, Fonck Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991; 83: 111–6PubMedCrossRefGoogle Scholar
  31. 31.
    Balkwill FR, Moodie EM. Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 1984; 44: 904–8PubMedGoogle Scholar
  32. 32.
    Sparano JA, O’Boyle K. The potential role for biological therapy in the treatment of breast cancer. Semin Oncol 1992; 19: 333–41PubMedGoogle Scholar
  33. 33.
    Vandenberg T, Skillings J. Phase II study of interferon alpha and tamoxifen in patients with metastatic breast cancer previously unresponsive to tamoxifen [abstract 1274]. Proc Am Assoc Cancer Res 1992; 33: 213Google Scholar
  34. 34.
    Macheledt JE, Buzdar AU, Hortobagyi GN, et al. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1991; 18: 165–70PubMedCrossRefGoogle Scholar
  35. 35.
    Wadler S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 1990; 17 (1 Suppl.): 16–21PubMedGoogle Scholar
  36. 36.
    Wadler S, Lembersky B, Atkins M, et al. Phase II trial of fluorouracil and recombinant alfa-2a interferon in patients with advanced colorectal carcinoma. J Clin Oncol 1991; 9: 1806–10PubMedGoogle Scholar
  37. 37.
    Sparano JA, Wadler S. 5-Fluorouracil plus α-interferon: modulation, intensification, or both? J Infusional Chemother 1992; 2: 142–5Google Scholar
  38. 38.
    Grem JL, McAtee N, Murphy RF, et al. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 1992; 9: 1811–20Google Scholar
  39. 39.
    Sparano JA, Wadler S, Diasio RB, et al. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 1993; 11: 1609–17PubMedGoogle Scholar
  40. 40.
    Schwartz EL, Hoffman M, O’Connor CO, et al. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 1992; 182: 1232–9PubMedCrossRefGoogle Scholar
  41. 41.
    Wadler S, Mao X, Schwartz EL. Recombinant alfa-2a-interferon augments 5-fluorouracil effects on nucleotide (dNTP) pools and DNA double strand breaks in human colon cancer cell lines [abstract]. Proc Am Assoc Cancer Res 1992; 33: 2539Google Scholar
  42. 42.
    Ashford R, Priestman T, Mott R, et al. Combining interferon with cytotoxic chemotherapy in patients with advanced breast cancer. Cancer Immunol Immunother 1986; 23: 217–9PubMedCrossRefGoogle Scholar
  43. 43.
    Sparano JA, Wadler S, Liebes L, et al. Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-α2b in patients with advanced breast cancer. Cancer Res 1993; 53: 3509–12PubMedGoogle Scholar
  44. 44.
    Walder S, Goldman M, Lyver A, et al. Phase I trial of 5-fluorouracil and recombinant α2a interferon in patients with advanced colorectal cancer. Cancer Res 1990; 50: 2056–9Google Scholar
  45. 45.
    Robert NJ, Taylor SG, Bowker B, et al. Phase I study of dose escalation of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) with granulocyte-macrophage colony stimulating factor (GM-CSF) in metastatic breast cancer: an Eastern Cooperative Oncology Group (ECOG) protocol. Proceedings of the 4th International Conference on Adjuvant Therapy of Breast Cancer 1992: 79PGoogle Scholar
  46. 46.
    Buzdar AU, Hortobagyi GN, Kau SC, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leucocyte α-interferon for stage II or III breast cancer. J Clin Oncol 1992; 10: 1540–6PubMedGoogle Scholar
  47. 47.
    Boldt DH, Ellis TM. Biologic effects of interleukin-2 administration on the immune system. In: Atkins MB, Mier JW, editors. Therapeutic applications of interleukin-2. New York: Marcel Dekker, 1993: 73–92Google Scholar
  48. 48.
    Rosenberg SA, Mule JS, Seir PJ, et al. Regression of established pulmonary metastasis and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin-2. J Exp Med 1985; 161: 1169–80PubMedCrossRefGoogle Scholar
  49. 49.
    LoRusso PM, Aukerman SL, Polin L, et al. Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems. Cancer Res 1990; 50: 5876–82PubMedGoogle Scholar
  50. 50.
    Morere JF, Boaziz C, Franks CR, et al. Continuous infusion (CI) or recombinant IL-2 (rIL-2) in 22 cases of advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1990; 9: 36Google Scholar
  51. 51.
    Sznol M, Hawkins MJ. Interleukin-2 in malignancies other than melanoma and renal cell carcinoma. In: Atkins MB, Mier JW, editors. Therapeutic applications of interleukin-2. New York: Marcel Dekker, 1993: 177–88Google Scholar
  52. 52.
    Walters R, Parkinson D, Talpaz, et al. A phase II trial of recombinant interleukin-2 (rIL-2, Hoffman-LaRoche) and recombinant alpha interferon (Roferon-A, Hoffman-LaRoche) (rIFN-α) in metastatic breast cancer. Proc Am Soc Clin Oncol 1990; 9: 36Google Scholar
  53. 53.
    Paciucci PA, Holland JF, Ryder JS, et al. Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin. Cancer Treat Rev 1989; 16 (Suppl.): 67–81PubMedCrossRefGoogle Scholar
  54. 54.
    Fao R. Does interleukin-2 have a role in the management of acute leukaemia. J Clin Oncol 1993; 11: 1817–25Google Scholar
  55. 55.
    Ferrara JLM, Deeg HG. Graft versus host disease. N Engl J Med 1991; 324: 667–74PubMedCrossRefGoogle Scholar
  56. 56.
    Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–62PubMedGoogle Scholar
  57. 57.
    Hood AF, Vogelsang GB, Black LP, et al. Acute graft-versus-host disease: development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745–50PubMedCrossRefGoogle Scholar
  58. 58.
    Glazier AD, Tutschka PJ, Farmer ER, et al. Graft-versus-host disease in cyclosporine A treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med 1983; 158: 1–8PubMedCrossRefGoogle Scholar
  59. 59.
    Natali PG, Giacomini P, Bigotti A, et al. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 1983; 43: 660–8PubMedGoogle Scholar
  60. 60.
    Kennedy MJ, Vogelsang GB, Beveridge RA, et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11: 478–84PubMedGoogle Scholar
  61. 61.
    Gottlieb DJ, Brenner MK, Heslop HE, et al. A phase I clinical trial of recombinant interleukin-2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer 1989; 60: 610–5PubMedCrossRefGoogle Scholar
  62. 62.
    Ahlert T, Kauffna M, Schirrmacher V, et al. Active specific immunotherapy (ASI) with virally modified autologous tumor cell vaccines in breast cancer. Br J Med 1990; 62(Suppl. 12): 15Google Scholar
  63. 63.
    Kantor J, Irvine K, Abrams S, et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992; 84: 1084–91PubMedCrossRefGoogle Scholar
  64. 64.
    Kantor J, Irvine K, Abrams S, et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992; 52: 6917–25PubMedGoogle Scholar
  65. 65.
    Durrant LG, Denton GWL, Jacobs E, et al. An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumors. Int J Cancer 1992; 50: 811–6PubMedCrossRefGoogle Scholar
  66. 66.
    Springer GF. T and Tn, general carcinoma autoantigens. Science 1984; 224: 1198–206PubMedCrossRefGoogle Scholar
  67. 67.
    Fung PYS, Madej R, Koganty R, et al. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990: 50; 4308–14PubMedGoogle Scholar
  68. 68.
    Singhal A, Fohn M, Hakomori S. Induction of alpha-N-acetylgalactosamine-O-serine/threonine (Tn)-antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 1991; 51: 1406–11PubMedGoogle Scholar
  69. 69.
    Springer GF, Desai P, Tegtmeyer H, et al. Pancarcinoma T/Tn antigen detects human carcinoma long before biopsy does and its vaccine prevents breast carcinoma recurrence. In: Bystryn J-C, et al., editors. Specific immunotherapy of cancer with vaccines. Ann NY Acad Sci 1993; 690: 355–7CrossRefGoogle Scholar
  70. 70.
    MacLean GD, Reddish M, Koganty RR, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus DETOX adjuvant. Cancer Immunol Immunother 1993; 36: 215PubMedCrossRefGoogle Scholar
  71. 71.
    Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of the human tumour-associated polymorphic epithelial mucin. J Biol Chem 1990; 265: 15286–93PubMedGoogle Scholar
  72. 72.
    Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51: 2908–16PubMedGoogle Scholar
  73. 73.
    Ding L, Lalani E-N, Reddish M, et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 1993; 36: 9–17PubMedCrossRefGoogle Scholar
  74. 74.
    Fendly BM, Kotts C, Vetterlein D, et al. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Resp Mod 1990; 9: 449–55Google Scholar
  75. 75.
    Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA 15-3 and CEA levels in patients with breast cancer. J Clin Oncol 4; 1452–550, 1986Google Scholar
  76. 76.
    Kalofonos HP, Stewart S, Epenetos AA. Antibody-guided diagnosis and therapy of malignant lesions. Int J Cancer 1988; 2: 74–80CrossRefGoogle Scholar
  77. 77.
    Cote R, Rosen PP, Lesser ML, et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991; 9: 1749–56PubMedGoogle Scholar
  78. 78.
    Anderson IC, Shpall EJ, Leslie DS, et al. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 1989; 49: 4659–64PubMedGoogle Scholar
  79. 79.
    Goodman GE, Hellstrom I, Brodzinsky L, et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990; 8: 1083–92PubMedGoogle Scholar
  80. 80.
    Bjorn MJ, Ring D, Frankel A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res 1985; 45: 1214–21PubMedGoogle Scholar
  81. 81.
    Bjorn MJ, Groetsema G, Scalapino L. Antibody-Pseudomonas exotoxin A conjugates cytotoxic to human breast cancer cells in vitro. Cancer Res 1986; 46: 3262–7PubMedGoogle Scholar
  82. 82.
    Ceriani RL, Blank E, Peterson, JA. Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components. Cancer Res 1987; 47: 532–40PubMedGoogle Scholar
  83. 83.
    Ceriani RL, Blank EW. Experimental therapy of human breast tumors with 131I-labeled monoclonal antibodies prepared against the human milk fat globule. Cancer Res 1988; 48: 4664–72PubMedGoogle Scholar
  84. 84.
    DeNardo SJ, Warhoe KA, O’Grady LF, et al. Radioimmunotherapy for breast cancer: treatment of a patient with I-131 L6 chimeric monoclonal antibody. Int J Biol Markers 1991; 6: 221–30PubMedGoogle Scholar
  85. 85.
    Divgi CR, Kemeny N, Kelson D, et al. Radioimmunotherapy with I-131 labeled monoclonal antibody (MAb) CC49 in patients with colorectal carcinoma [abstract]. 7th International Conference on MAb Immuno-conjugates for Cancer; 1992 March; San DiegoGoogle Scholar
  86. 86.
    Weiner LM, O’Dwyer J, Kitson J, et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res 1989; 49: 4062–7PubMedGoogle Scholar
  87. 87.
    Gould BJ, Borowitz MJ, Groves ES, et al. Phase I study of an anti-breast immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 1989; 81: 775–81PubMedCrossRefGoogle Scholar
  88. 88.
    Maier AL, Xu FJ, Hester S, et al. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res 1991; 51: 5361–9PubMedGoogle Scholar
  89. 89.
    Tecce R, Digiesi G, Savarese A, et al. Characterization of cytotoxic activity of saporin anti-GP185/HER-2 immunotoxins. Int J Cancer 1993; 55: 122–7PubMedCrossRefGoogle Scholar
  90. 90.
    Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261: 212–5PubMedCrossRefGoogle Scholar
  91. 91.
    Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327–33PubMedCrossRefGoogle Scholar
  92. 92.
    Senter PD, Katsuragi T, Sakai T, et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjug Chem 1991; 2: 447–51PubMedCrossRefGoogle Scholar
  93. 93.
    Rosenberg SA. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 1985; 75: 595–603PubMedGoogle Scholar
  94. 94.
    Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142; 3714–25PubMedGoogle Scholar
  95. 95.
    Balch CM, Riley LB, Bae JY, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990; 125: 200PubMedCrossRefGoogle Scholar
  96. 96.
    Mathoulin MP, Xerri L, Jacquemier J, et al. Unrestricted T-cell receptor V-region gene repertoire in tumor-infiltrating lymphocytes from human breast carcinomas. Cancer 1993; 72: 506–10PubMedCrossRefGoogle Scholar
  97. 97.
    Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancers. J Natl Cancer Inst 1993; 85: 622–31PubMedCrossRefGoogle Scholar
  98. 98.
    Tsai S-CJ, Gansbacher B, Tait L, et al. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 1993; 85: 546–53PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Joseph A. Sparano
    • 1
  • Kevin O’Boyle
    • 1
  1. 1.Albert Einstein Cancer CenterMontefiore Medical CenterBronxUSA

Personalised recommendations